Intelligence Feed event · Policy · 2026-09-19

    Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions

    Question

    Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions

    Direct answer

    Teva Pharmaceutical Industries presented real-world observational data evaluating UZEDY (risperidone extended-release injectable suspension) in patient populations with schizophrenia and bipolar I disorder. The findings showed higher treatment adherence and continuity relative to comparator long-acting injectable and oral therapies. The study reported that improved patient persistence on UZEDY corresponded with reduced emergency department visits and lowered overall healthcare resource utilization, providing clinical evidence to support insurance reimbursement and hospital formulary adoption.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/teva-clinical-evidence-highlights-uzedy-treatment-retention-and-cost-reductions-35abe8

    POLICY
    Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
    Teva Pharmaceutical Industries presented real-world observational data evaluating UZEDY (risperidone extended-release injectable suspension) in patient populations with schizophrenia and bipolar I disorder. The findings showed higher treatment adherence and continuity relative to comparator long-acting injectable and oral therapies. The study reported that improved patient persistence on UZEDY corresponded with reduced emergency department visits and lowered overall healthcare resource utilization, providing clinical evidence to support insurance reimbursement and hospital formulary adoption.
    TEVA
    Impact
    67
    SEP 19
    SIG
    85%
    TEVA
    Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
    Teva Pharmaceutical Industries presented real-world observational data evaluating UZEDY (risperidone extended-release injectable suspension) in patient populations with schizophrenia and bipolar I disorder. The findings showed higher treatment adherence and continuity relative to comparator long-acting injectable and oral therapies. The study reported that improved patient persistence on UZEDY corresponded with reduced emergency department visits and lowered overall healthcare resource utilization, providing clinical evidence to support insurance reimbursement and hospital formulary adoption.
    → Demonstrated reductions in emergency hospital utilization improve commercial formulary coverage positioning and drive TEVA specialty injectable volume growth.
    Impact
    Teva Pharmaceutical Industries presented real-world observational data evaluating UZEDY (risperidone extended-release injectable suspension) in patient populations with schizophrenia and bipolar I disorder. The findings showed higher treatment adherence and continuity relative to comparator long-acting injectable and oral therapies. The study reported that improved patient persistence on UZEDY corresponded with reduced emergency department visits and lowered overall healthcare resource utilization, providing clinical evidence to support insurance reimbursement and hospital formulary adoption.
    Affected
    TEVA
    Transmission
    Demonstrated reductions in emergency hospital utilization improve commercial formulary coverage positioning and drive TEVA specialty injectable volume growth.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TEVAcommercial formulary access expansion and specialty prescription volume growthUp1-3mReal-world study showed UZEDY demonstrated superior treatment continuity and reduced emergency healthcare utilization.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month